Literature DB >> 1829514

A comparison of cephalosporins and penicillins in the treatment of group A beta-hemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial copathogenicity.

M E Pichichero1, P A Margolis.   

Abstract

Although penicillin has been the antibiotic of choice for therapy of Group A beta-hemolytic streptococcal pharyngitis for more than four decades, reports of bacteriologic and clinical treatment failures with penicillin have increased in recent years. We conducted a meta-analysis of 19 studies to examine whether oral cephalosporins were associated with lower failure rates than oral penicillin in the treatment of Group A beta-hemolytic streptococcal pharyngitis. The overall bacteriologic cure rate for penicillin was 84% (95% confidence interval (CI), 82%, 86%) compared with 92% (95% CI, 91%, 94%) among patients treated with cephalosporins (P less than 0.0001). The overall clinical cure rate in the penicillin groups was 89% (95% CI, 87%, 91%) compared with 95% (95% CI, 94%, 96%) in the cephalosporin group (P less than 0.001). There was no significant difference between the cephalosporins and the penicillins with respect to adverse events. There may be clinical circumstances in which treatment of Group A beta-hemolytic streptococcal pharyngitis with cephalosporins is indicated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1829514     DOI: 10.1097/00006454-199104000-00002

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  29 in total

Review 1.  Antibacterial therapy for acute group a streptococcal pharyngotonsillitis: short-course versus traditional 10-day oral regimens.

Authors:  Itzhak Brook
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  Consumption of antibiotics in Sweden, 1975 to 1992: pharmacoeconomic and clinical aspects.

Authors:  S R Norrby
Journal:  Pharmacoeconomics       Date:  1992-09       Impact factor: 4.981

Review 3.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

Review 4.  Clinical and economic considerations in the use of third-generation oral cephalosporins.

Authors:  S T Chambers; D R Murdoch; M J Pearce
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

Review 5.  Optimum treatment of streptococcal pharyngitis.

Authors:  F Scaglione; G Demartini; M M Arcidiacono; J P Pintucci
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 6.  Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.

Authors:  L R Wiseman; P Benfield
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

7.  Randomized evaluation of benzathine penicillin V twice daily versus potassium penicillin V three times daily in the treatment of group A streptococcal pharyngitis. Pharyngitis Study Group.

Authors:  A Kaufhold
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

8.  Azithromycin versus cefaclor in the treatment of pediatric patients with acute group A beta-hemolytic streptococcal tonsillopharyngitis.

Authors:  J Cremer; C Wallrauch; D Milatovic; I Braveny
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

9.  Evaluation of potential factors contributing to microbiological treatment failure in Streptococcus pyogenes pharyngitis.

Authors:  S M Kuhn; J Preiksaitis; G J Tyrrel; T Jadavji; D Church; H D Davies
Journal:  Can J Infect Dis       Date:  2001-01

10.  Cefprozil versus penicillin V in treatment of streptococcal tonsillopharyngitis.

Authors:  D Milatovic; D Adam; H Hamilton; E Materman
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.